API | samalizumab

samalizumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Samalizumab is a humanized monoclonal antibody designed for oncology indications. Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
samalizumab

More Chemistry

Pharmacology

Mechanism of Action:
- OX-2 membrane glycoprotein (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

alxn6000 | alxn-6000 | samalizumab

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue